What is William Blair’s Estimate for MaxCyte Q1 Earnings?

MaxCyte, Inc. (NASDAQ:MXCT) – Stock analysts at William Blair issued their Q1 2025 earnings per share estimates for MaxCyte in a report issued on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will earn ($0.10) per share for the quarter. The consensus estimate for MaxCyte’s current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte’s Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.34) EPS.

MXCT has been the subject of a number of other reports. Stifel Nicolaus cut their price target on MaxCyte from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday. BTIG Research set a $6.00 price target on MaxCyte and gave the stock a “buy” rating in a report on Wednesday.

MaxCyte Trading Up 7.5 %

Shares of NASDAQ MXCT opened at $3.29 on Friday. MaxCyte has a 1-year low of $2.76 and a 1-year high of $5.26. The stock has a fifty day simple moving average of $4.17 and a two-hundred day simple moving average of $3.97. The firm has a market cap of $348.61 million, a price-to-earnings ratio of -9.68 and a beta of 1.35.

Institutional Investors Weigh In On MaxCyte

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Cadian Capital Management LP raised its position in shares of MaxCyte by 14.1% in the fourth quarter. Cadian Capital Management LP now owns 9,344,424 shares of the company’s stock worth $38,873,000 after buying an additional 1,155,476 shares in the last quarter. Mirabella Financial Services LLP purchased a new stake in shares of MaxCyte in the fourth quarter worth $15,392,000. River Global Investors LLP raised its position in shares of MaxCyte by 57.7% in the fourth quarter. River Global Investors LLP now owns 3,253,192 shares of the company’s stock worth $13,494,000 after buying an additional 1,190,630 shares in the last quarter. Mudita Advisors LLP raised its position in shares of MaxCyte by 2.2% in the fourth quarter. Mudita Advisors LLP now owns 3,223,407 shares of the company’s stock worth $13,409,000 after buying an additional 69,966 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of MaxCyte by 2.0% in the third quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company’s stock worth $9,628,000 after buying an additional 47,960 shares in the last quarter. Hedge funds and other institutional investors own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.